WO2003050044A1 - Electrochemically activated water for the treatment of cystitis - Google Patents
Electrochemically activated water for the treatment of cystitis Download PDFInfo
- Publication number
- WO2003050044A1 WO2003050044A1 PCT/ZA2002/000197 ZA0200197W WO03050044A1 WO 2003050044 A1 WO2003050044 A1 WO 2003050044A1 ZA 0200197 W ZA0200197 W ZA 0200197W WO 03050044 A1 WO03050044 A1 WO 03050044A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous
- containing solution
- solution
- predominantly
- mixed
- Prior art date
Links
- 201000003146 cystitis Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 5
- 239000000243 solution Substances 0.000 claims abstract description 150
- 150000001450 anions Chemical class 0.000 claims abstract description 61
- 239000007800 oxidant agent Substances 0.000 claims abstract description 58
- 230000001590 oxidative effect Effects 0.000 claims abstract description 58
- 210000003932 urinary bladder Anatomy 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 56
- 208000015181 infectious disease Diseases 0.000 claims abstract description 33
- 239000007864 aqueous solution Substances 0.000 claims abstract description 29
- 230000001684 chronic effect Effects 0.000 claims abstract description 29
- 230000002458 infectious effect Effects 0.000 claims abstract description 26
- 230000001154 acute effect Effects 0.000 claims abstract description 21
- 230000000813 microbial effect Effects 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 230000003213 activating effect Effects 0.000 claims abstract description 10
- 230000004968 inflammatory condition Effects 0.000 claims abstract description 9
- 150000001768 cations Chemical class 0.000 claims description 39
- 239000003638 chemical reducing agent Substances 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 241000894007 species Species 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- 238000005868 electrolysis reaction Methods 0.000 claims description 4
- 230000002008 hemorrhagic effect Effects 0.000 claims description 4
- 230000003118 histopathologic effect Effects 0.000 claims description 4
- 230000027939 micturition Effects 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 3
- 201000003139 chronic cystitis Diseases 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 201000005661 acute cystitis Diseases 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010069645 Reduced bladder capacity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010050822 Suprapubic pain Diseases 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000003016 quadriplegic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
- C02F1/4674—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation with halogen or compound of halogens, e.g. chlorine, bromine
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4676—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electroreduction
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/46109—Electrodes
- C02F2001/46152—Electrodes characterised by the shape or form
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2305/00—Use of specific compounds during water treatment
- C02F2305/02—Specific form of oxidant
- C02F2305/023—Reactive oxygen species, singlet oxygen, OH radical
Definitions
- This invention relates to a method of and solutions for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture.
- any infectious condition of the urinary bladder will be associated with inflammatory changes and a concomitant hypersensitization of the bladder mucosa and/or underlying musculature, it is the progressive and ultimately chronic manifestations of the primary clinical condition that results in the irritative voiding symptoms and supra-pubic pain associated with bladder filling.
- histological changes in the mucosal lining of the bladder, as well as underlying tissue may undergo keratinising metaplastic changes which, although non-malignant, may progress to conditions of patent malignancy unless resolved or controlled.
- Treatment may vary from rudimentary pH modulation, i.e. urinary acidifiers to alter the internal environment suited to the bacterial populations present both in and on the bladder mucosa, through to rigorous antimicrobial therapy where the specific antimicrobial has been typed to ensure optimal efficacy against the offending microbial populations.
- antimicrobials are selected on the basis of their specific path of urinary excretion, thus ensuring optimal concentrations of antimicrobial agents in close proximity to the sources of infection.
- a method of treating both acute and chronic infectious cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion- containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
- the electrochemically activated, aqueous solution may be selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution; and a cation- containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation-containing solution.
- the predominantly anion-containing solution is referred to hereinafter for brevity as the “anolyte solution” or “anolyte”, and the predominantly cation-containing solution is referred to as the “catholyte solution” or “catholyte”.
- the electrochemically activated, aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt.
- the salt may be selected from the group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi-carbonates; - phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and - phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts.
- the electrochemically activated, aqueous solution may be produced from a relatively low concentration aqueous salt solution.
- the aqueous salt solution concentration may be between 0.0001% to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
- the anolyte and the catholyte may be produced by an electrochemical reactor or so- called electrolysis device, having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co-axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement.
- the electrochemical cell may have predetermined design and geometrical relationships, ensuring optimum fluid flow and re-circulation patterns.
- the cell may have a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm 2 , thus causing turbulent fluid flow there through so as to ensure maximum exposure of the solutions to the electric field.
- the anolyte and the catholyte may be produced in the electrochemical cell under predetermined operational parameters, including a relatively low current, preferably of about 5A to 8A, and a relatively high voltage, preferably of about 6V to 48V, and more preferably between 8V and 24V, thus providing a relatively high voltage gradient or electric field intensity at the interface between the electrode surface and electrolyte, estimated to be about 10 6 V/cm.
- the salt solution may be electrolysed to produce the anolyte and the catholyte with mixed oxidant and mixed reductant species. These species may be labile and after about 96 hours, the concentration and activity of the various activated species may reduce substantially with relatively little, alternatively no active residues remaining.
- the anolyte solution may have a redox potential of about between +300mV and +1200mV.
- the anolyte solution may have a pH of between 2 and 8, and preferably a pH of 7.
- the anolyte solution may include mixed oxidant species such as CIO; CIO “ ; HCIO; OH “ ; HO 2 " ; H 2 O 2 ; O 3 ; S 2 O 8 2" and CI 2 O 6 2 .
- the catholyte solution generally may have a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100mV and preferably of about -800mV.
- the catholyte solution may include mixed reductant species such as OH " ; H 3 " ; O 2 ; H 2 ; HO 2 ; HO 2 " and
- anolyte may contain organic radicals and other components such as Cl 2 , HCIO, CIO ' , CIO", Cl ⁇ HO 2 , HO 2 , O 2 , HO ⁇
- Catholyte may contain HO ' , H 3 0 2 ⁇ 0 2 " , H0 2 " , H 2 O 2 , H 2 , HO, H 2 " ,
- solutions has shown varying quantities of aluminium, calcium, magnesium, manganese, potassium, sodium, molybdenum, ammonium, orthophosphate, silica and chloride.
- the varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, preferably the different flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences, may be adjustable so as to produce anolyte and catholyte with suitable physical and chemical characteristics, with specific conductivity, redox potential and pH, concentration of "activated species" and other characteristics, for particular applications.
- an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic infectious cystitis, wherein the aqueous, mixed oxidant, predominantly anion- containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
- an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic infectious cystitis.
- an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
- an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
- an aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that it possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
- an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
- a method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents
- the method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
- a method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder
- the method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
- a method of treatment of a human or animal body suffering from acute and/or chronic cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a
- a method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing
- the method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
- Inflammation of the bladder wall present in patients suffering from cystitis can result from one or more of three main causes, namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment.
- microbial infections namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment.
- Each of these causes of cystitis is characterised therein that is responds to specific optimal treatment methods.
- Microbially induced cystitis responds best to treatment by anolyte which comprises anti-microbial properties
- the immunogenic and radiation induced cystitis would respond better to treatment by catholyte, which has anti- oxidant properties and promotes healing.
- electrochemically activated aqueous solutions as direct infusions or instillations has been shown to offer significant relief or resolution of clinical disease of the urinary bladder and associated anatomical architecture as may be associated with chronic inflammation arising from neurogenic voiding dysfunction, intractable haemorrhagic cystitis secondary to pelvic radiation therapy, and chronic recurrent cystitis of various non-specific microbial and/or inflammatory aetiologies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hydrology & Water Resources (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method of treating acute and chronic infectious cystitis. The method includes the steps of electrochemically activating a dilute aqueous solution such that it includes an aqueous, mixed oxidant, predominantly anion-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution. The invention also includes a solution for treating acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
Description
ELECTROCHEMICALLY ACTIVATED WATER FOR THE TREATMENT OF CYSTITIS
Technical field
This invention relates to a method of and solutions for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture.
Background art
While any infectious condition of the urinary bladder will be associated with inflammatory changes and a concomitant hypersensitization of the bladder mucosa and/or underlying musculature, it is the progressive and ultimately chronic manifestations of the primary clinical condition that results in the irritative voiding symptoms and supra-pubic pain associated with bladder filling. Aside from the overt clinical symptoms evidenced during chronic cystitis, histological changes in the mucosal lining of the bladder, as well as underlying tissue, may undergo keratinising metaplastic changes which, although non-malignant, may progress to conditions of patent malignancy unless resolved or controlled.
Long term or chronic indwelling catheterisation of quadriplegic or paraplegic patients may result in chronic or recurrent urogenital microbial infections of a primarily ascending nature. It is well established that biofilm proliferation in indwelling catheters serves as the primary focus of recurrent infection, and sub-optimal anti-microbial therapy may lead to progressive resistance to the previously efficacious therapeutic agents. Protracted microbial infections of the bladder lumen give rise to concurrent inflammatory changes in the superficial mucosal layer and thereafter also in the deeper underlying tissues and musculature.
In advanced cases, chronic changes of the bladder architecture may result in patent symptoms of cystitis without any microbial agent being present and the focus of the inflammatory changes has been adjudged to be interstitial in nature. These chronic, recurrent bouts of interstitial inflammation of the urinary bladder wall and its surrounding tissue constitute a substantially hyperaesthetic and debilitating disease. The condition has been shown to be primarily associated with women, although up to 10% of cases may manifest in men.
Patients diagnosed with interstitial cystitis are limited by the variety and value of medical and surgical interventions available for the resolution of symptoms. Treatment may vary from rudimentary pH modulation, i.e. urinary acidifiers to alter the internal environment suited to the bacterial populations present both in and on the bladder mucosa, through to rigorous antimicrobial therapy where the specific antimicrobial has been typed to ensure optimal efficacy against the offending microbial populations. Similarly, antimicrobials are selected on the basis of their specific path of urinary excretion, thus ensuring optimal concentrations of antimicrobial agents in close proximity to the sources of infection.
In cases of protracted microbial infection, with a scenario of potential antimicrobial resistance developed by the microbe populations, these infections of the transitional epithelium of the bladder mucosa and the underlying musculature, may give rise to nonspecific inflammatory immunogenic conditions of the tissue. These conditions may progress to full-blown symptoms of cystitis without an infectious microbial component and have been described as being akin to a hypersensitivity reaction by the body against its own tissue types.
In cases of patients receiving radiation therapy, whether generalised or specific to the pelvic region, a frequent sequel to the intervention is that of haemorrhagic cystitis, the duration and severity of which is directly dependent on the magnitude and frequency of the radiation treatment. Repeated and long-term radiation treatments have been shown to be associated with mucosal ulceration as well as telangiectatic changes of the vasculature of the bladder wall and the overt haematuria is a direct consequence of these changes.
Object of the invention It is accordingly an object of this invention to provide a more effective method for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture that will overcome or at least minimise the above problems.
Disclosure of the invention
According to the invention there is provided a method of treating both acute and chronic infectious cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-
containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The electrochemically activated, aqueous solution may be selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution; and a cation- containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation-containing solution.
The predominantly anion-containing solution is referred to hereinafter for brevity as the "anolyte solution" or "anolyte", and the predominantly cation-containing solution is referred to as the "catholyte solution" or "catholyte".
The electrochemically activated, aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt. The salt may be selected from the group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi-carbonates; - phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and - phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts.
The electrochemically activated, aqueous solution may be produced from a relatively low concentration aqueous salt solution. Depending on the particular process being performed, and the method for producing the electrochemically activated solution (e.g. with or without pre-dilution of the feed solutions), the aqueous salt solution concentration may be between 0.0001% to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
The anolyte and the catholyte may be produced by an electrochemical reactor or so- called electrolysis device, having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co-axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement. The electrochemical cell may have predetermined design and geometrical relationships, ensuring optimum fluid flow and re-circulation patterns. The cell may have a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm2, thus causing turbulent fluid flow there through so as to ensure maximum exposure of the solutions to the electric field.
The anolyte and the catholyte may be produced in the electrochemical cell under predetermined operational parameters, including a relatively low current, preferably of about 5A to 8A, and a relatively high voltage, preferably of about 6V to 48V, and more preferably between 8V and 24V, thus providing a relatively high voltage gradient or electric field intensity at the interface between the electrode surface and electrolyte, estimated to be about 106 V/cm.
The salt solution may be electrolysed to produce the anolyte and the catholyte with mixed oxidant and mixed reductant species. These species may be labile and after about 96 hours, the concentration and activity of the various activated species may reduce substantially with relatively little, alternatively no active residues remaining.
The anolyte solution may have a redox potential of about between +300mV and +1200mV. The anolyte solution may have a pH of between 2 and 8, and preferably a pH of 7. Depending on the salt(s) in the feed stream used in the activation process, the anolyte solution may include mixed oxidant species such as CIO; CIO"; HCIO; OH"; HO2 " ; H2O2; O3; S2O8 2" and CI2O6 2.
The catholyte solution generally may have a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100mV and preferably of about -800mV. Depending on the salt(s) in the feed stream, the catholyte solution may include mixed reductant species such as OH"; H3 "; O2; H2 ; HO2 ; HO2 " and
Depending on the source of the water and the salt used, anolyte may contain organic radicals and other components such as Cl2, HCIO, CIO', CIO", Cl\ HO2, HO2 , O2, HO\
O3> 02 ", 3O2, 02, O", H3O+, Cϊ, H\ H2O2, Cl20, CI02\ HCI, CI2O7, S2O8 2", C2O6 2", HCIO,
H2SO4, and HS03CI. Catholyte may contain HO', H302\ 02 ", H02 ", H2O2, H2, HO, H2 ",
NaOH, KOH, Ca(OH)2 and Mg(OH)2. Analysis of the inorganic components of these
solutions has shown varying quantities of aluminium, calcium, magnesium, manganese, potassium, sodium, molybdenum, ammonium, orthophosphate, silica and chloride.
The varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, preferably the different flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences, may be adjustable so as to produce anolyte and catholyte with suitable physical and chemical characteristics, with specific conductivity, redox potential and pH, concentration of "activated species" and other characteristics, for particular applications.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic infectious cystitis, wherein the aqueous, mixed oxidant, predominantly anion- containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic infectious cystitis.
According to a further aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or
interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
According to yet a further aspect of the invention there is provided an aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that it possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
According to yet a further aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of
hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the
human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and any associated infectious microbial agents, and the solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly
anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
Specific embodiment of the invention
Experiments were conducted on patients with intractable and recurrent interstitial cystitis that had proven to be refractory to all current and traditional means of therapeutic intervention.
Inflammation of the bladder wall present in patients suffering from cystitis can result from one or more of three main causes, namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment. Each of these causes of cystitis is characterised therein that is responds to specific optimal treatment methods. Microbially induced cystitis responds best to treatment by anolyte which comprises anti-microbial properties, whereas the immunogenic and
radiation induced cystitis would respond better to treatment by catholyte, which has anti- oxidant properties and promotes healing.
However, the applicant has found that although anolyte treatment is sufficient in microbially induced cystitis, and catholyte in immunogenic and radiation induced cystitis, treatment of patients with the other one of the two solutions (catholyte or anolyte, as the case may be) in both cases have increased recovery. It is believed that this is so because of the following reasons. After the causative microbes have been eradicated by treatment with the anolyte in the case of microbially induced cystitis, follow-up treatment with catholyte promotes quicker and more complete healing. Similarly, in the case of immunogenic and radiation induced cystitis, treatment with anolyte, in conjunction with treatment with catholyte, will ensure eradication of any opportunistic infectious agents.
Example:
Fifteen patients with chronic progressive Interstitial Cystitis (IC) were treated according to the following protocol.
All patients were admitted for overnight evaluation and an indwelling catheter was inserted into the bladder. The following morning, the freshly generated, mixed oxidant anolyte solution (pH=7, ORP=+750mV) was diluted to a 50% strength with normal saline (0,9% m/v) and 1000ml of the 50% strength solution was infused into the bladder lumen for 6 hours. In patients where the chronic nature of the condition had reduced bladder capacity to less than 1000ml, the maximum volume to accommodate the reduced bladder capacity was administered as an instillation. The mixed oxidant perfusate was subsequently drained from the bladder and flushed with 100ml of sterile
saline (0,9% m/v).
Thereafter 1000ml of the mixed predominantly anti-oxidant radical catholyte solution (pH=11 , ORP=-850mV) was infused into the bladder by way of the indwelling catheter for a further six-hour period.
Following drainage of the anti-oxidant solution, and removal of the indwelling catheter, the patients were discharged from the medical facility.
Of the fifteen patients treated to date, no relapse of symptoms of the original condition have occurred and all patients have reported a significant improvement in urine retention capacity, reduced frequency of voluntary bladder emptying, and an extended duration of inter-voiding interval. These significant improvements were achieved without perpetuation of the adjunct antimicrobial and analgesic therapy prescribed for the original condition.
The use of electrochemically activated aqueous solutions as direct infusions or instillations has been shown to offer significant relief or resolution of clinical disease of the urinary bladder and associated anatomical architecture as may be associated with chronic inflammation arising from neurogenic voiding dysfunction, intractable haemorrhagic cystitis secondary to pelvic radiation therapy, and chronic recurrent cystitis of various non-specific microbial and/or inflammatory aetiologies
It will be appreciated that many variations in detail are possible without departing from the scope or spirit of the invention as defined in the claims.
Claims
1. A method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
2. The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into the lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
3. A method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
5. A method of treatment of a human or animal body suffering from acute and/or chronic cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation- containing solution and the aqueous, mixed oxidant, predominantly anion- containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and any associated infectious microbial agents, and the solution.
6. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation- containing solution; and a cation-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution.
7. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is prepared by means of electrolysis of an aqueous solution of a salt.
8. The method as claimed in claim 7 characterised therein that the salt is selected from a group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi- carbonates; -phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and -phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts.
9. The method as claimed in claim 7 characterised therein that the electrochemically activated, aqueous solution is produced from an aqueous salt solution having a concentration of between 0.0001 % to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
10. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is produced by an electrochemical reactor or electrolysis device having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co- axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement, wherein the electrochemical cell has a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm2, for causing turbulent fluid flow there through.
11. The method as claimed in claims 1 to 5 characterised therein that the anolyte and catholyte are produced in the electrochemical cell under a relatively low current of about 5A to 8A, and a relatively high voltage of about 6V to 48V, and more preferably between 8V and 24V.
12. The method as claimed in claims 1 to 5 characterised therein that the mixed oxidant and mixed reductant species of the anolyte and catholyte are labile such that after about 96 hours, the concentration and activity of the various activated species reduce substantially with relatively little, alternatively no active residues remaining.
13. The method as claimed in claims 1 to 5 characterised therein that the anolyte solution has a redox potential of about between +300 mV and +1200 mV, and a pH of between 2 and 8, and preferably a pH of 7; and wherein the catholyte solution has a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100 mV, and preferably of about -800 mV.
14. The method as claimed in claims 1 to 5 characterised therein that the anolyte solution includes mixed oxidant species such as CIO; CIO"; HCIO; OH"; HO2 "; H2O2; O3; S2O8 2" and CI2O6 2.
15. The method as claimed in claims 1 to 5 characterised therein that the catholyte solution includes mixed reductant species such as OH"; H3 "; O2; H2 ; HO2'; HO2 " and O2 ".
16. The method as claimed in claims 1 to 5 characterised therein that the anolyte contains organic radicals and other components such as Cl2, HCIO, CIO', CIO-,
CI-, HO2, HO2\ O2, HO, O3, O2 , 3O2, O2, O\ H3O+, Cl\ H\ H2O2, CI2O, CIO2 ', HCI,
CI2O7, S2O8 2", C2O6 2", HCIO, H2SO4, and HSO3CI.
17. The method as claimed in claims 1 to 5 characterised therein that the catholyte contains organic radicals and other components such as HO", H3O2 ", O2 ", HO2\
H2O2, H2, HO, H2 ', NaOH, KOH, Ca(OH)2 and Mg(OH)2.
18. The method as claimed in claims 1 to 5 characterised therein that the physical and chemical characteristics, including specific conductivity, redox potential and pH, concentration of activated species and other characteristics of the anolyte and catholyte are adjusted for particular applications by varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, including flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences.
19. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic microbially induced cystitis, wherein the aqueous, mixed oxidant, predominantly anion-containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
20. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic microbially induced cystitis.
21. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
22. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
23. Use of an aqueous, mixed reductant, predominantly cation-containing solution in the treatment of acute and chronic immunogenic and radiation induced cystitis, wherein the aqueous, mixed reductant, predominantly cation-containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
24. Use of an aqueous, mixed reductant, predominantly cation-containing solution in the preparation of a medicament for use in the treatment of acute and chronic immunogenic and radiation induced cystitis.
25. An aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that is possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
26. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
27. A method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
28. A method of treatment of a human or animal body substantially as herein exemplified with reference to the accompanying examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002351430A AU2002351430A1 (en) | 2001-12-10 | 2002-12-09 | Electrochemically activated water for the treatment of cystitis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2001/10119 | 2001-12-10 | ||
| ZA200110119 | 2001-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003050044A1 true WO2003050044A1 (en) | 2003-06-19 |
Family
ID=25589401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/ZA2002/000197 WO2003050044A1 (en) | 2001-12-10 | 2002-12-09 | Electrochemically activated water for the treatment of cystitis |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002351430A1 (en) |
| WO (1) | WO2003050044A1 (en) |
| ZA (1) | ZA200404611B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006103314A1 (en) * | 2005-03-30 | 2006-10-05 | Oy Keskuslaboratorio-Centrallaboratorium Ab | Electrochemical method for preparing microbiocidal solutions |
| EP1826183A1 (en) * | 2006-02-24 | 2007-08-29 | Kimihiro Sato | Ionized water and method of producing same |
| US7618655B2 (en) * | 2003-11-21 | 2009-11-17 | Cytotools Gmbh | Method for the preparation of aqueous solutions of reactive chlorine compounds |
| US8137730B2 (en) | 2007-12-21 | 2012-03-20 | Sun-Maid Growers Of California | Power spraying of agricultural products with wrinkled skins |
| RU2452535C1 (en) * | 2010-09-29 | 2012-06-10 | Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения и социального развития Российской Федерации | Method of treating chronic cystitis |
| US9089602B2 (en) | 2008-07-25 | 2015-07-28 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| RU2593889C1 (en) * | 2015-04-28 | 2016-08-10 | Тимур Асланбекович Гяургиев | Method for integrated treatment of chronic bacterial recurrent cystitis in females at aggravation stage |
| US9572810B2 (en) | 2010-07-22 | 2017-02-21 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| EP3593862A1 (en) * | 2018-07-12 | 2020-01-15 | Azad Pharma AG | Electrochemically activated salt solution |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0792584A1 (en) * | 1994-07-29 | 1997-09-03 | Toto Ltd. | Strongly acidic sterile water containing low-concentration hypochlorous acid, method of forming strongly acidic sterile water containing low-concentration hypochlorous acid, apparatus therefor, and apparatus for forming and delivering strongly acidic sterile water containing low-concentration hypoch |
| US5731008A (en) * | 1990-05-23 | 1998-03-24 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbicides |
| WO1999020287A1 (en) * | 1997-10-23 | 1999-04-29 | Radical Waters Ip (Pty) Ltd | The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals |
| WO1999020286A1 (en) * | 1997-10-23 | 1999-04-29 | Radical Waters Ip (Pty) Ltd | A composition for the treatment of legionella pneumophila and a method for such treatment |
| JPH11209292A (en) * | 1998-01-22 | 1999-08-03 | Morinaga Milk Ind Co Ltd | Skin disease treatment |
| RU2138270C1 (en) * | 1996-05-06 | 1999-09-27 | Басалаева Надежда Львовна | Method of prophylaxis of postabortive endometritis |
| WO2001054704A1 (en) * | 2000-01-12 | 2001-08-02 | Novacal Pharmaceuticals, Llc | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| RU2195970C2 (en) * | 2000-05-24 | 2003-01-10 | Ханты-Мансийский государственный медицинский институт | Method for draining and healing intracavitary pathological focus |
-
2002
- 2002-12-09 AU AU2002351430A patent/AU2002351430A1/en not_active Abandoned
- 2002-12-09 WO PCT/ZA2002/000197 patent/WO2003050044A1/en not_active Application Discontinuation
-
2004
- 2004-06-10 ZA ZA200404611A patent/ZA200404611B/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731008A (en) * | 1990-05-23 | 1998-03-24 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbicides |
| EP0792584A1 (en) * | 1994-07-29 | 1997-09-03 | Toto Ltd. | Strongly acidic sterile water containing low-concentration hypochlorous acid, method of forming strongly acidic sterile water containing low-concentration hypochlorous acid, apparatus therefor, and apparatus for forming and delivering strongly acidic sterile water containing low-concentration hypoch |
| RU2138270C1 (en) * | 1996-05-06 | 1999-09-27 | Басалаева Надежда Львовна | Method of prophylaxis of postabortive endometritis |
| WO1999020287A1 (en) * | 1997-10-23 | 1999-04-29 | Radical Waters Ip (Pty) Ltd | The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals |
| WO1999020286A1 (en) * | 1997-10-23 | 1999-04-29 | Radical Waters Ip (Pty) Ltd | A composition for the treatment of legionella pneumophila and a method for such treatment |
| JPH11209292A (en) * | 1998-01-22 | 1999-08-03 | Morinaga Milk Ind Co Ltd | Skin disease treatment |
| WO2001054704A1 (en) * | 2000-01-12 | 2001-08-02 | Novacal Pharmaceuticals, Llc | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| RU2195970C2 (en) * | 2000-05-24 | 2003-01-10 | Ханты-Мансийский государственный медицинский институт | Method for draining and healing intracavitary pathological focus |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI Section Ch Week 199942, Derwent World Patents Index; Class B06, AN 1999-497074, XP002235492 * |
| DATABASE WPI Section Ch Week 200038, Derwent World Patents Index; Class B06, AN 2000-440110, XP002235494 * |
| DATABASE WPI Section PQ Week 200318, Derwent World Patents Index; Class P34, AN 2003-181797, XP002235493 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8728537B2 (en) | 2003-11-21 | 2014-05-20 | Cytotools Ag | Compositions for improvement of wound healing |
| US7618655B2 (en) * | 2003-11-21 | 2009-11-17 | Cytotools Gmbh | Method for the preparation of aqueous solutions of reactive chlorine compounds |
| US8349369B2 (en) | 2003-11-21 | 2013-01-08 | Cytotools Gmbh | Method and pharmaceutical composition for improvement of wound healing |
| WO2006103314A1 (en) * | 2005-03-30 | 2006-10-05 | Oy Keskuslaboratorio-Centrallaboratorium Ab | Electrochemical method for preparing microbiocidal solutions |
| EP1826183A1 (en) * | 2006-02-24 | 2007-08-29 | Kimihiro Sato | Ionized water and method of producing same |
| EP2228346A1 (en) * | 2006-02-24 | 2010-09-15 | Skyview Enterprises | Ionized water and method of producing same |
| US8137730B2 (en) | 2007-12-21 | 2012-03-20 | Sun-Maid Growers Of California | Power spraying of agricultural products with wrinkled skins |
| US9089602B2 (en) | 2008-07-25 | 2015-07-28 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9089511B2 (en) | 2008-07-25 | 2015-07-28 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9775798B2 (en) | 2008-07-25 | 2017-10-03 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US11110053B2 (en) | 2008-07-25 | 2021-09-07 | Reven Pharmaceuticals Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9572810B2 (en) | 2010-07-22 | 2017-02-21 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| US9867849B2 (en) | 2010-07-22 | 2018-01-16 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| US11202798B2 (en) | 2010-07-22 | 2021-12-21 | Reven Pharmaceuticals, Inc. | Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| RU2452535C1 (en) * | 2010-09-29 | 2012-06-10 | Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения и социального развития Российской Федерации | Method of treating chronic cystitis |
| RU2593889C1 (en) * | 2015-04-28 | 2016-08-10 | Тимур Асланбекович Гяургиев | Method for integrated treatment of chronic bacterial recurrent cystitis in females at aggravation stage |
| EP3593862A1 (en) * | 2018-07-12 | 2020-01-15 | Azad Pharma AG | Electrochemically activated salt solution |
| WO2020011870A1 (en) * | 2018-07-12 | 2020-01-16 | Azad Pharma Ag | Electrochemically activated salt solution |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200404611B (en) | 2010-08-25 |
| AU2002351430A1 (en) | 2003-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5079010A (en) | Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals | |
| US6583176B2 (en) | Aqueous disinfectant | |
| WO2003050044A1 (en) | Electrochemically activated water for the treatment of cystitis | |
| WO2001054704A1 (en) | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing | |
| JP2003520820A5 (en) | ||
| CN104958830B (en) | A kind of anti-infective therapy of subacidity electrolyzed oxidizing water gynaecology equipment | |
| EP1221980B1 (en) | Electrolytic generation of iodine for preventing implant induced infections | |
| CN108849971A (en) | A kind of preparation and its application method using acidulous hypochlorous acid's type thimerosal | |
| JP2004530659A (en) | Methods and formulations for antitumor and antimetastatic effects | |
| US5222936A (en) | Intracorporeal iontophoretic method | |
| CN103008683A (en) | Preparation method for high-efficient monomer silver solution as well as high-efficient monomer silver gel and lotion | |
| CN113398334A (en) | Carbon quantum dot hydrogel composite scaffold material, preparation method and application | |
| US6992073B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion | |
| WO2010004653A1 (en) | Eradicating agent and eradication method for helicobacter pylori | |
| CN108926577A (en) | A kind of method that electric potential water is used for Wound antibiotic healing cleaning-nursing | |
| WO2023125763A1 (en) | Povidone iodine-containing temperature-sensitive gelling preparation | |
| CN110354390A (en) | A kind of diabetes Wound healing preparation and its application | |
| CN116370406A (en) | Nanometer enzyme injectable hydrogel for treating hemorrhoids | |
| RU2422377C2 (en) | Biocidal concentrate | |
| JPH0710762A (en) | Gargle for stomatitis | |
| CN1281271C (en) | Biological bacteria inhibitor | |
| CN114099567B (en) | Sterilizing and deodorizing spray for shoes and socks and preparation method thereof | |
| JPH07258099A (en) | Apparatus for producing cleaning liquid and cleaning liquid produced thereby | |
| RU2246323C2 (en) | Method for curative sounding | |
| WO2024163469A2 (en) | Peracetic acid antimicrobial composition system and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 200404611 Country of ref document: ZA |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |